SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn’s Disease in Adults

AbbVie announced that the US FDA has approved SKYRIZI® as the first and only specific IL-23 inhibitor for the treatment of adults with moderately to severely active Crohn’s disease.
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News